Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin H Voss

Showing results (31-40 of 141) with videos related to

Pageof 15
Sort By:
Clinical Genitourinary Cancer|May 19, 2021
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell CarcinomaSimon Chowdhury, Jeffery R Infante, Robert Hawkins, et al.
Cancer|April 23, 2013
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and olderDarren R Feldman, Martin H Voss, Erin P Jacobsen, et al.
Journal for Immunotherapy of Cancer|October 5, 2018
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancyMichael Lattanzi, Fang-Ming Deng, Luis A Chiriboga, et al.
The Lancet. Oncology|November 13, 2018
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort studyMartin H Voss, Albert Reising, Yuan Cheng, et al.
Clinical Genitourinary Cancer|September 26, 2015
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted DrugsChung-Han Lee, Andreas M Hötker, Martin H Voss, et al.
Clinical Genitourinary Cancer|February 13, 2021
Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 PandemicMichal Sarfaty, Darren R Feldman, Michael J Morris, et al.
The Oncologist|June 12, 2016
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell CarcinomaMaria I Carlo, Ana M Molina, Yulia Lakhman, et al.
British Journal of Cancer|October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinomaChung-Han Lee, Robert J Motzer, Hilary Glen, et al.
Cancer|September 8, 2011
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinomaAna M Molina, Darren R Feldman, Martin H Voss, et al.
Journal for Immunotherapy of Cancer|February 11, 2021
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockadeJason Beattie, Hira Rizvi, Paige Fuentes, et al.
Pageof 15

Showing results (31-40 of 141) with videos related to

Sort By:
Pageof 15
Clinical Genitourinary Cancer|May 19, 2021
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell CarcinomaSimon Chowdhury, Jeffery R Infante, Robert Hawkins, et al.
Cancer|April 23, 2013
Clinical features, presentation, and tolerance of platinum-based chemotherapy in germ cell tumor patients 50 years of age and olderDarren R Feldman, Martin H Voss, Erin P Jacobsen, et al.
Journal for Immunotherapy of Cancer|October 5, 2018
Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancyMichael Lattanzi, Fang-Ming Deng, Luis A Chiriboga, et al.
The Lancet. Oncology|November 13, 2018
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort studyMartin H Voss, Albert Reising, Yuan Cheng, et al.
Clinical Genitourinary Cancer|September 26, 2015
Bevacizumab Monotherapy as Salvage Therapy for Advanced Clear Cell Renal Cell Carcinoma Pretreated With Targeted DrugsChung-Han Lee, Andreas M Hötker, Martin H Voss, et al.
Clinical Genitourinary Cancer|February 13, 2021
Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 PandemicMichal Sarfaty, Darren R Feldman, Michael J Morris, et al.
The Oncologist|June 12, 2016
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell CarcinomaMaria I Carlo, Ana M Molina, Yulia Lakhman, et al.
British Journal of Cancer|October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinomaChung-Han Lee, Robert J Motzer, Hilary Glen, et al.
Cancer|September 8, 2011
Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinomaAna M Molina, Darren R Feldman, Martin H Voss, et al.
Journal for Immunotherapy of Cancer|February 11, 2021
Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockadeJason Beattie, Hira Rizvi, Paige Fuentes, et al.
Pageof 15